ClinicalTrials.Veeva

Menu
R

Research Solutions of Arizona | Litchfield Park, AZ

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Mirikizumab
Remibrutinib
IgPro20
MK-7240-001
S-600918
Tulisokibart
MK-7240
Guselkumab
Amlitelimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 14 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Active, not recruiting
Crohn's Disease
Drug: Mirikizumab

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will ha...

Active, not recruiting
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Mirikizumab

The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study...

Enrolling
Ulcerative Colitis
Drug: IV Placebo
Drug: SC Placebo

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: Mirikizumab

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Active, not recruiting
Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: Placebo

The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.

Active, not recruiting
Hereditary Angioedema (HAE)
Biological: CSL312

This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)

Active, not recruiting
Hereditary Angioedema
Biological: CSL312

This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).The purpose of thi...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab

This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (markete...

Not yet enrolling
Hereditary Angioedema
Biological: Garadacimab

Trial sponsors

CSL Behring logo
Lilly logo
Novartis logo
Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo
Sanofi logo
Shionogi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems